Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Research
Drugs Made In America Acquisition Corp. functions as a special purpose acquisition company, commonly known as a blank check company. Its core mission is to seek out and ultimately acquire one or more existing businesses or their assets. This acquisition strategy encompasses a variety of transactional methods, such as corporate mergers, capital stock exchanges, direct asset purchases, stock acquisitions, or broader corporate reorganizations.
Market snapshot
- Symbol
- DMAA
- Price
- $10.63
- Day change
- +0.09%
- Market cap
- $358.4M
- P/E ratio
- 36.73x
- 52-week range
- 10.17-10.63
- Sector
- Financial Services
- Industry
- Shell Companies
Peer companies
- Centurion Acquisition Corp. (ALF)
- Live Oak Acquisition Corp. V Class A Ordinary Shares (LOKV)
- Mountain Lake Acquisition Corp. (MLAC)
- Oyster Enterprises II Acquisition Corp (OYSE)
- Renatus Tactical Acquisition Corp I Class A Ordinary Shares (RTAC)
- SIM Acquisition Corp. I (SIMA)
- Titan Acquisition Corp. (TACH)
- Berto Acquisition Corp. (TACO)
Recent insider activity
- Drugs Made In America Acquisition LLC — P-Purchase (30000 shares) on 2025-02-18
- Drugs Made In America Acquisition LLC — P-Purchase (30000 shares) on 2025-02-18
- Stockwell Lynn — P-Purchase (30000 shares) on 2025-02-18
- Stockwell Lynn — P-Purchase (30000 shares) on 2025-02-18
- Drugs Made In America Acquisition LLC — P-Purchase (400000 shares) on 2025-01-29
Open Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.